13/11/2003
ReGen Therapeutics Plc (‘the Company’), a company developing Colostrinin™ as a potential therapy for Alzheimer’s disease, announces that it is today sending to shareholders a circular containing a notice convening an extraordinary general meeting of the Company (the ‘Circular’) for 11.00 a.m. on 10 December 2003 (‘EGM’).
On 5 November 2003, the Company disposed of its remaining shareholding in New Opportunities Investment Trust plc, which will raise approximately £278,000, before expenses, for the Company. In addition the Board is currently in negotiations for further funding of the Company to pursue its strategy of developing Colostrinin™ and of acquiring complimentary businesses. Accordingly, the Board is seeking at the EGM renewal of its authorities to issue shares and/ or other securities so as to facilitate such fundraising and/or acquisitions.
Following the issue on 22 July 2003 of 63,600,000 ordinary shares of the Company to new and existing shareholders pursuant to a placing, the Directors of the Company are also seeking at the EGM renewal of their general authorities to issue shares and/or other securities, such general authority being last granted to them at the Annual General Meeting of the Company held on 10 June 2003.
Copies of the Circular will be available, for collection only, free of charge to the public, from the Company, Suite 406, Langham House, 29-30 Margaret Street, London W1W 8SA during normal office hours on any day (Saturdays, Sundays excepted) from today until 12 December 2003.
For further information, please contact:
Andrew Marshall
Marshall Robinson Roe
Tel No 020 7960 6007